Recent Comments
Archived Facts

Diabetes drug maker Amylin Pharmaceuticals Inc. reported a larger fourth-quarter loss Monday after it ended a partnership with Eli Lilly & Co., which gave Amylin all the rights to the drug Byetta and newly approved Bydureon.

Popular Posts:

Related Posts:

Leave a Reply